Industry | 制造业 | ||||||||||||||||||||||||
Company Introduction | 公司以“精粹色谱科技,致力人类健康”为己任,以“打造国际色谱行业第一品牌”为奋斗目标,专注于色谱装备、耗材及应用技术,经过二十多年持续自主研发创新,掌握了具有汉邦特色的“一心两核多用”色谱技术。“一心”即被誉为色谱“心脏”的色谱柱技术,“两核”即色谱系统集成和色谱应用两大核心技术,“多用”即围绕色谱技术开发的多种药物分离纯化设备、耗材等产品技术,广泛应用于工业生产和实验室研发等应用场景。通过持续研发,汉邦科技突破了色谱线性放大等分离纯化技术难题,实现了样品从克级、十克级、百克级到千克级的分离纯化线性放大,产品和技术广泛应用于抗体、重组蛋白、疫苗、胰岛素、多肽、造影剂、抗生素等药物和天然产物的研发和生产,打破了国外相关技术和产品的长期垄断,已成为国内色谱分离纯化装备研发、生产和产业化领先企业,有力推动了色谱分离纯化装备的国产替代和下游制药行业的产业升级。分离纯化是药物生产中的核心环节,直接决定药物的纯度和质量,也是影响其生产成本的重要因素。制备色谱技术是一种新型的分离纯化技术,与结晶、萃取、精馏等传统分离技术相比,具有分离效率高、应用范围广、选择性强、操作条件温和、便于在线检测等诸多优势,已成为高纯药物生产的必要手段。制备色谱/层析系统是基于制备色谱技术,适应科技进步和生产需要发展起来的一种新型、高效、节能、环保的药物分离纯化装备,在药物生产过程中的应用日益广泛,是胰岛素、多肽、抗体、重组蛋白、疫苗、核酸、造影剂、抗生素等各类药物生产的关键设备之一。此外,制备色谱在天然产物、保健品、化妆品、石油化工和精细化工等领域均有重要应用,市场空间广阔。 国内高端制药装备起步相对较晚,国内药物研发和生产过程中需要的制备色谱/层析系统等核心生产设备长期依赖进口,设备采购和维护成本居高不下,直接影响了医药产业的升级和发展。随着我国医药产业改革持续推进,“医保控费”、“仿制药一致性评价”和“药品带量采购”等政策陆续出台,对制药企业的成本控制和质量标准提出了更高要求。另外,在国际形势复杂的大背景下,医药行业需要逐步摆脱对进口产品的依赖,对高质量国产设备的需求逐步放量,开发优质色谱纯化设备和应用方案的重要性日益凸显,国产制备色谱/层析系统市场潜力巨大。公司专注于色谱分离纯化产品领域,通过长期投入自主研发构建了丰富的色谱产品矩阵,针对工业生产和实验室研发推出了小分子药物分离纯化设备、大分子药物分离纯化设备两大类产品线,小分子药物分离纯化设备主要包括小分子液相色谱、模拟移动床色谱系统、超临界流体色谱系统等。大分子药物分离纯化设备主要包括自动层析系统、手动层析柱、自动超滤系统、连续流层析系统、自动在线配液系统、核酸合成系统等设备,形成能够满足实验室研发到工业化生产的全产品体系,为国内外制药企业提供高品质纯化设备和应用方案。此外,公司持续开展色谱填料/层析介质的研发,产业化基地已启动规划建设,进一步延伸产业链,丰富业务布局,增强公司综合实力。公司长期坚持自主创新。 截至本招股说明书签署日,公司已获得授权的发明专利共36项,其中境内发明专利27项,海外发明专利9项;曾主持或牵头承担省级以上科研和产业化项目15项,其中包括国家重大科学仪器设备开发专项项目“超临界流体色谱仪的研制与应用开发”、国家科技型中小企业技术创新基金项目“药物等制备用模拟移动床色谱分离纯化装置”等国家级项目6项。公司先后获得国家知识产权示范企业、国家专精特新“小巨人”企业等荣誉称号。 | ||||||||||||||||||||||||
Main Business | 为制药、生命科学等领域提供专业的分离纯化装备、耗材与技术服务。 | ||||||||||||||||||||||||
Legal Representative | 张大兵 | ||||||||||||||||||||||||
Top Executives |
|
||||||||||||||||||||||||
Top 5 Shareholder |
|
||||||||||||||||||||||||
Company Secretary | 汤业峰 | ||||||||||||||||||||||||
Solicitors | 北京德恒律师事务所 | ||||||||||||||||||||||||
Auditors | 天健会计师事务所(特殊普通合伙) | ||||||||||||||||||||||||
Tel No | 86-517-83706908 | ||||||||||||||||||||||||
Fax No | 86-517-83706903 | ||||||||||||||||||||||||
Website | www.hanbon.com.cn | ||||||||||||||||||||||||
IR@hanbon.com.cn | |||||||||||||||||||||||||
Company Address |
|
||||||||||||||||||||||||
Listing Date | 16/05/2025 | ||||||||||||||||||||||||
Shares Capital |
|
||||||||||||||||||||||||
EPS(RMB)* | ¥ 1.200 | ||||||||||||||||||||||||
DPS(RMB)* | -- | ||||||||||||||||||||||||
NBV Per Share(RMB)* | ¥ 11.210 | ||||||||||||||||||||||||
Market Capitalization(RMB) | 0.763B |
![]() |
Only Chinese content is avaliable |
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
* | Unadjusted Data |
Information provided by: etnet | ||
Terms and Conditions |
Risk Disclosure: |
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
Disclaimer: |
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |